Crescita Therapeutics Inc.

CTX.TOTSXHealthcare● Active

$0.79

+$0.00(+0.00%)

Market Cap$14705011

P/E Ratio—

52W High$0.79

52W Low$0.4

Avg Volume35K

Open$0.79

Beta-0.12

Net Income Financials Revenue

Crescita Therapeutics Inc. (CTX.TO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CTX.TO · net income · updated Jun 9, 2026

Core profitability metrics

CTX.TO · net income · margin · TTM · CAGR

Net income was −$92,000 for FY2025 (fiscal year ending 2025-12-31), up 96.7% year-over-year. Net profit margin was -0.4%. Based on available data, Crescita Therapeutics Inc. has been profitable since at least 2018.

FY2025 Net Income−$92,000▲ +96.7% YoY

Trailing 12M (TTM)−$320,000trailing 4 quarters sum

Net Profit Margin-0.4%−$92,000 ÷ $21.1M

YoY Change+96.7%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2018

▸ FMP /income-statement · Annual · CTX.TO net income history · CTX.TO profit margin

Annual net income data

CTX.TO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$92,000▲ +96.7%-0.4%$21.1M

FY2024Loss−$2.8M▼ 38.5%-14.0%$19.6M

FY2023Loss−$2.0M▼ 330.4%-11.3%$17.5M

FY2022$862,000▲ +178.0%3.7%$23.5M

FY2021Loss−$1.1M▼ 3086.5%-6.6%$16.8M

Net income vs peers (Healthcare)

CTX.TO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Crescita Therapeutics Inc.YOU

CTX.TO

−$92,000+96.7%-0.4%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Crescita Therapeutics Inc. (CTX.TO) reported net income of −$92,000 for FY2025 (fiscal year ending 2025-12-31), up 96.7% year-over-year. The net profit margin was -0.4% — meaning the company kept $-0.00 of every dollar of revenue as profit.

Based on available data, Crescita Therapeutics Inc. has been profitable since at least 2018. Net income reached a peak of $2.4M in FY2018. Data available for 12 fiscal years.

Crescita Therapeutics Inc.'s net profit margin was -0.4% for FY2025, based on the latest annual results.

Investors sometimes search for "Crescita Therapeutics Inc. net worth" — the company's market capitalization is a separate figure from CTX.TO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CTX.TO net income · 4 questions

Crescita Therapeutics Inc. is not currently profitable on an annual basis. The company reported a net loss of $92,000 for FY2025.

is CTX.TO profitabledoes CTX.TO make a profitCTX.TO profitabilityCTX.TO profitable company

▸ Source: FMP /income-statement · GAAP · Crescita Therapeutics Inc. · Crescita Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026